Conferences - Results from #320

Viewing 321-340 of 11531 articles

AUA 2024: Nivolumab plus Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin Alone in Patients with Previously Untreated Unresectable or Metastatic Urothelial Carcinoma: Results of Analyses to Characterize Benefit in Responders from the CheckMate 901 Trial

AUA 2024: Risk Stratification for Adjuvant Therapy with High Risk RCC

AUA 2024: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from JAVELIN Bladder 100 in Subgroups Defined by First-Line Chemotherapy Regimen and Analysis of OS from Start of First-Line Chemotherapy

UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024

AUA 2024: mCRPC: Key Updates in Radioligand Therapy, PSMA Sensitive Disease

AUA 2024: Whitmore Lecture – Optimizing Outcomes in High-Risk Localized Prostate Cancer – Cure is Possible when Cure is Necessary.

AUA 2024: First Results of NURE-Combo: A Phase 2 Study of Neoadjuvant Nivolumab and Nab-Paclitaxel Followed by Postsurgical Adjuvant NIVO in Patients with Muscle-Invasive Bladder Cancer

AUA 2024: Panel Discussion: Artificial Intelligence

AUA 2024: Outcomes of Minimally Invasive Nephrectomy Following Immune-Checkpoint Inhibitor Therapy: Data from a Multicenter Study

AUA 2024: Panel Discussion: Obstructive Pyelonephritis Due to Ureteral Stone

AUA 2024: Response to Primary Chemoablation With UGN-102 in Patients with New or Recurrent LG IR NMIBC: Post-hoc Analysis of the ATLAS Trial

AUA 2024: Genomic Signatures Associated with Adverse Pathologic Features at Radical Prostatectomy Among Active Surveillance Eligible Men

AUA 2024: High Decipher Score Defines the Subgroup Most at Risk of Metastatic Progression Among Patients with Lower Grade Tumors Classified as NCCN High-Risk Based on Elevated Prostate-Specific Antigen Level Alone

AUA 2024: Comparing Methocarbamol to Oxybutynin for Stent Colic – A Prospective Randomized Controlled Trial

AUA 2024: First Prospective Clinical Assessment of The ILY Robotic Flexible Ureteroscopy Platform.

AUA 2024: Automated Renal Volume Measurement using Artificial Intelligence: Correlation to Post-Operative Renal Function after Radical and Partial Nephrectomy

AUA 2024: Journal of Urology Lecture: Empowering Communities: Fostering Prostate Cancer Awareness and Resilience Among Men of Color

AUA 2024: Development and External Validation of an Artificial Intelligence-Based Tool for PROGression Risk Assessment in Non-Muscle Invasive Bladder Cancer (PROGRxN-BCa)

AUA 2024: Comprehensive Evaluation of Response to Immune Checkpoint Blockade in Primary Tumor: Radiographic and Radiomic Features Predict Pathologic Response in Primary Tumor

AUA 2024: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC): Phase 3 Preliminary Results

12
13
14
15
16
17
18
19
20
21